Brief: Antengene Says XPOVIO Approved For New Indication In DLBCL In China
05/07/2024 14:44
July 5 (Reuters) - Antengene Corporation Ltd 6996.HK :
* XPOVIO® (SELINEXOR) APPROVED FOR NEW INDICATION IN DLBCL
IN
CHINA, BRINGING A NEW TREATMENT OPTION TO PATIENTS IN THE
COUNTRY
* ANTENGENE CORP: APPROVALS IN OTHER ASEAN MARKETS
ANTICIPATED IN
H2 2024
Source text for Eikon: ID:nPn5m6FRFa
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106